IDiyas

For the Inventor, By the Inventor

Canton, MA, United States of America

Christopher Ryan Butler

LinkedIn
USPTO Granted Patents = 35 

 

 

Average Co-Inventor Count = 6.1

ph-index = 10

Forward Citations = 191(Granted Patents)


Company Filing History:

goldMedal35 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
35 patents (USPTO):
1. 12398119 - Piperazine azaspiro derivatives (2025-08-26),
2. 12187727 - Methods for antagonizing a melanocortin 4 receptor (2025-01-07),
3. 11905284 - 5,7-dihydro-pyrrolo-pyridine derivatives (2024-02-20),
4. 11643412 - Melanocortin 4 receptor antagonists and uses thereof (2023-05-09),
5. 11524954 - Piperazine azaspiro derivatives (2022-12-13),
6. 11198692 - Dihydro-pyrrolo-pyridine derivatives (2021-12-14),
7. 10858373 - Heterocyclic spiro compounds as MAGL inhibitors (2020-12-08),
8. 10723711 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors (2020-07-28),
9. 10626125 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors (2020-04-21),
10. 10604519 - 5,7-dihydro-pyrrolo-pyridine derivatives (2020-03-31),
11. 10428034 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors (2019-10-01),
12. 10329308 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors (2019-06-25),
13. 10253042 - N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides (2019-04-09),
14. 10112958 - N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides (2018-10-30),
15. 10028962 - 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides (2018-07-24),

Title: **Exploring the Innovations of Christopher Ryan Butler**

Introduction

Christopher Ryan Butler is an accomplished inventor based in Canton, MA, USA, who has significantly contributed to the field of medicinal chemistry and pharmacology. With an impressive portfolio of 34 patents, he has dedicated his career to developing innovative solutions for various medical conditions.

Latest Patents

Among his notable inventions, Butler's latest patents include groundbreaking methodologies for antagonizing the melanocortin 4 receptor (MC4R). His work details methods of treating MC4R-related conditions, diseases, or disorders through administering specific compounds. Notably, his patent describes 5,7-dihydro-pyrrolo-pyridine derivatives and their derivatives, which are utilized for treating a variety of disorders, including Alzheimer's Disease, schizophrenia, chronic pain, addiction, and sleep disorders. These advancements represent significant strides in the therapeutic landscape for conditions associated with MC4R.

Career Highlights

Christopher Ryan Butler is currently employed at Pfizer Corporation, a global leader in the pharmaceutical industry. His expertise in developing innovative treatment methods not only showcases his dedication to advancing medical science but also highlights his role in a prestigious organization that is at the forefront of drug discovery and development.

Collaborations

Throughout his career, Butler has collaborated with talented individuals in the field, including colleagues like Michael Aaron Brodney and Brian Thomas O'Neill. These collaborations foster an environment of innovation, enabling advancements and refinements in their research endeavors, leading to the successful development of effective therapeutic agents.

Conclusion

In summary, Christopher Ryan Butler's work exemplifies the spirit of innovation in the realm of pharmaceuticals. His intellectual contributions are paving the way for new treatments that can improve the quality of life for countless individuals. As a prolific inventor with a solid foundation in research, Butler continues to exemplify what it means to be at the cutting edge of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…